Investment Info

Urologix, Inc., based in Minneapolis, is the leading provider for in-office BPH therapy. The company develops, manufactures, markets and distributes minimally invasive medical products for BPH treatment. Urologix' Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Cooled ThermoTherapy™ product line includes the CoolWave® and Targis® Control Units and the CTC Advance® and Targis® catheter families. The Prostiva® RF Therapy System distributed by Urologix delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. Both of these products provide safe, effective and lasting relief of the symptoms and obstruction due to BPH.

Urologix' patented Cooled ThermoTherapy™ technology is creating effective treatment options for a wide range of patients with BPH. Cooled ThermoTherapy delivers precisely targeted microwave energy that heats and destroys enlarged prostatic tissue while unique cooling mechanisms protect surrounding healthy tissue and enhances patient comfort.

Prostiva® RF Therapy provides direct visualization with 360 degrees of precision which allows the urologist to treat the median and lateral lobe as well as asymmetrical prostates. This system is able to reach intraprostatic temperatures of 110°C allowing it to create a lesion in the tissue causing significant necrosis in just two minutes and 20 seconds. Experienced physicians report good patient tolerability with the utilization of a prostate block.

Prostiva® is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.

¹Data on file at Urologix, Inc.

Stock Quote
ULGX (Common Stock)
ExchangeOTCQB (US Dollar)
Financial Status IndicatorN
Price$0.10
Change (%) Stock is Down 0.02 (16.67%)
Volume15,200
Data as of 09/19/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
Download Documentation 2013 Annual Report
Recent NewsMore >>
DateTitle 
08/19/14Urologix Reports Fourth Quarter and Fiscal Year 2014 Results
Recent Highlights Urologix restructured the company in April 2014 which reduced cash utilization in the fourth quarter to $98,000 Cost-effectiveness data covering Cooled ThermoTherapyTM presented at 2014 AUA Annual Meeting in May MINNEAPOLIS, Aug. 19, 2014 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today reported financial results for its fourth quarter and fiscal year e... 
Printer Friendly Version
08/13/14Urologix to Host Its Fiscal Year 2014 Fourth Quarter Conference Call
MINNEAPOLIS, Aug. 13, 2014 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX) will host a conference call to present fourth quarter and fiscal year 2014 results on Tuesday, August 19, 2014 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-877-415-3180 and enter the Participant Passcode 30328726 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, C... 
Printer Friendly Version
05/06/14Urologix Reports Fiscal Year 2014 Third Quarter Results
Third quarter revenue totaled $3.4 million Cash balance of $816,000 as of March 31, 2014 Annualized expenses reduced by over $4.0 million since January 1, 2014 MINNEAPOLIS, May 6, 2014 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today reported financial results for its fiscal third quarter ended March 31, 2014. Operating Results for the Third Quarter of Fiscal Year 2014 ... 
Printer Friendly Version
04/30/14Urologix to Host Its Fiscal Year 2014 Third Quarter Conference Call
MINNEAPOLIS, April 30, 2014 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX) will host a conference call to present fiscal year 2014 third quarter results on Tuesday, May 6, 2014 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1--866-515-2911 and enter the Participant Passcode 73790575 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Ex... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Urologix, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.